3,9-Diaza-bicyclo<3.3.1>nonan | 280-98-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3,9-Diaza-bicyclo<3.3.1>nonan
• 英文别名: 3,9-Diazabicyclo[3.3.1]nonane
• CAS: 280-98-8
• 化学式: C₇H₁₄N₂
• mdl: MFCD19217450
• 分子量: 126.202
• InChiKey: PJDJTXWCVQUXKZ-UHFFFAOYSA-N

物化性质

• 沸点：
  62-64 °C(Press: 2 Torr)
• 密度：
  0.950±0.06 g/cm3(Predicted)
• 熔点：
  83-84 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] 3,6-DIAZABICYCLOS[3.1.1]HEPTANE DERIVATIVES WITH ANALGESIC ACTIVITY<br/>[FR] DERIVES DE 3,6-DIAZABICYCLO[3.1.1]HEPTANE PRESENTANT UNE ACTIVITE ANALGESIQUE
  申请人：UNIV DEGLI STUDI MILANO

  公开号：WO2005108402A1

  公开（公告）日：2005-11-17

  The invention relates to compounds of general formula (I), wherein R and R1, different from one another, are: a C2-C8 straight or branched acyl group; and a group of formula (II), wherein B and R2 are as defined in the description. The compounds (I) have higher central analgesic activity than morphine and are substantially free from the side effects of morphine or other central analgesics. The invention further relates to a process for the preparation of the compounds (I).

  本发明涉及具有通用公式（I）的化合物，其中R和R1彼此不同，分别为：C2-C8直链或支链酰基团；以及公式（II）的基团，其中B和R2如描述中定义。化合物（I）具有比吗啡更高的中枢镇痛活性，并且基本上没有吗啡或其他中枢镇痛药的副作用。本发明还涉及制备化合物（I）的方法。
• [EN] NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE- AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS D'ESTER 3,8-DIAZA-BICYCLO[3.2.1]OCTANE- AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-ACIDE CARBOXYLIQUE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA RECAPTURE DU NEUROTRANSMETTEUR MONOAMINES
  申请人：NEUROSEARCH AS

  公开号：WO2009109517A1

  公开（公告）日：2009-09-11

  This invention relates to novel 3,8-diaza-bicyclo[3.2.1]octane-and 3,9-diaza- bicyclo[3.3.1]nonane-3-carboxylic acid ester derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. Formula (I).

  这项发明涉及作为单胺神经递质再摄取抑制剂有用的新型3,8-二氮杂双环[3.2.1]辛烷和3,9-二氮杂双环[3.3.1]壬烷-3-羧酸酯衍生物。在其他方面，该发明涉及将这些化合物用于治疗方法以及包括该发明化合物的药物组合物。公式（I）。
• [EN] THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS THIAZOLO-PYRIMIDINE THÉRAPEUTIQUEMENT ACTIFS
  申请人：UCB PHARMA SA

  公开号：WO2013068458A1

  公开（公告）日：2013-05-16

  A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

  一系列噻唑并[5,4-d]嘧啶衍生物的化学式(I)或其N-氧化物，或其药用可接受的盐或溶剂：(I) Q代表化学式(Qa)、(Qb)、(Qc)、(Qd)或(Qe)的基团，在治疗和/或预防各种人类疾病方面具有益处，包括炎症性、自身免疫和肿瘤性疾病；病毒性疾病；以及器官和细胞移植排斥。
• Therapeutically Active Thiazolo-Pyrimidine Derivatives
  申请人：UCB Pharma S.A.

  公开号：US20140315885A1

  公开（公告）日：2014-10-23

  A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

  一系列噻唑并[5,4-d]嘧啶衍生物的化学式(I)或其N-氧化物，或其药用可接受的盐或溶剂：(I) Q代表化学式(Qa)、(Qb)、(Qc)、(Qd)或(Qe)的基团，在治疗和/或预防各种人类疾病方面具有益处，包括炎症性、自身免疫和肿瘤性疾病；病毒性疾病；以及器官和细胞移植排斥反应。
• PYRAZINECARBOXAMIDE COMPOUND
  申请人：ASTELLAS PHARMA INC.

  公开号：US20140323463A1

  公开（公告）日：2014-10-30

  [Problem] A compound which is useful as an inhibitor on EGFR T790M mutation kinase activity is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory action on an EGFR T790M mutation kinase, and have found that a pyrazinecarboxamide compound has an inhibitory action on an EGFR T790M mutation kinase, thereby completing the present invention. The pyrazinecarboxamide compound of the present invention has an inhibitory action on an EGFR T790M mutation kinase, and can be used as an agent for preventing and/or treating EGFR T790M mutation positive cancer, in another embodiment, EGFR T790M mutation positive lung cancer, in a still other embodiment, EGFR T790M mutation positive non-small cell lung cancer, in further still another embodiment, EGFR T790M mutation protein positive cancer, in further still another embodiment, EGFR T790M mutation protein positive lung cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant lung cancer, and in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer, or the like.

  提供一种作为EGFR T790M突变激酶活性抑制剂的化合物。 解决方案的手段 本发明人调查了一种对EGFR T790M突变激酶具有抑制作用的化合物，并发现吡嗪羧酰胺化合物对EGFR T790M突变激酶具有抑制作用，从而完成了本发明。本发明的吡嗪羧酰胺化合物对EGFR T790M突变激酶具有抑制作用，并可用作预防和/或治疗EGFR T790M突变阳性癌症的药剂，在另一实施例中，EGFR T790M突变阳性肺癌，在另一实施例中，EGFR T790M突变阳性非小细胞肺癌，在进一步的另一实施例中，EGFR T790M突变蛋白阳性癌症，在进一步的另一实施例中，EGFR T790M突变蛋白阳性肺癌，在进一步的另一实施例中，EGFR酪氨酸激酶抑制剂耐药癌症，在进一步的另一实施例中，EGFR酪氨酸激酶抑制剂耐药肺癌，在进一步的另一实施例中，EGFR酪氨酸激酶抑制剂耐药非小细胞肺癌等。